Aborificant
Aborificant
Aborificant
BY
EBSU/2017/88639
OCTOBER, 2021
ABSTRACT
Abortifacient is any drug or chemical preparation that induces abortion. Abortion is the
expulsion of a fetus from the uterus before it has reached the stage of viability (in human
beings,usually about the 20th week of gestation). An abortion may occur spontaneously or by
induction. The most common agents of modern medical abortion includes Misoprostol and
Mifepristone. These drugs acts as an anti-progesterone or progesterone blockers which prevents
progesterone from mediating their biological effects in the body (in the presence of progesterone,
these drugs acts as a competitive progesterone receptor antagonist, it causes decidual necrosis
which leads to detachment of the pregnancy, It acts on the endometrial vessels to disrupt the
pregancy’s blood supply). The route through which the active substance take from application
location to the location where it has its target effect is usually rather a matter of
pharmacokinetics (concerning the process of uptake, distribution, and elimination of drugs).
Risks and adverse effects of abortifacient includes uterine perforation, cervical laceration, injury
to the intestines-bladder-blood vessels, maternal death. The effective use of contraceptives,
avoiding unintended pregnancy can help to reduce the rate of abortion in our country. The
strategies that effectively prevent unsafe abortion is an investment that results not only in
reduced human loss and suffering but also in net economic gain for the countries involved.
REFERENCES
Banerjee, Amrita; Ibsen, Kelly; Brown, Tyler; Chen, Renwei; Agatemor, Christian; and
Mitragotri, Samir (2018). Ionic liquids for oral insulin delivery. Proceedings of the
National Academy of Sciences: 20(17): 22-33.
Bhatti, K.Z; Nguyen, A.T; Stuart, G.S (2017). "Medical Abortion Reversal: Science and Politics
Meet". American Journal of Obstetrics and Gynecology. 218 (3): 315.el-315.
Chen, Melissa J.; Creinin, Mitchell, D. (2015), Mifepristone With Buccal Misoprostol for
Medical Abortion, Obstetrics and Gynecology. 126(1): 12-21
Ciato, Denis; Mumbach, Aizhar G.; Paez-Pereda, Marcelo; Stalla, and Günter K. (2016).
Currently used and investigational drugs for Cushing's disease. Expert Opinion on
Investigational Drugs, 26(1): 75-84.
Henkel, R.C.; Andrea, M. and Kate, A. (2018). "Advances in the management of early
pregnancy loss". Current Opinion in Obstetrics and Gynecology, 30(6): 419-424.
Iyioha, B.A. and Irehobhude, 0. (2015). Comparative health law and policy : critical
perspectives on Nigerian and global health law. Taylor and Francis. 978(1): 4724-3675.
Jones, S. Rachel, K.; Jerman, M. and Jenna, N. (2017). Abortion Incidence and Service
Availability in the United States 2014. Perspectives on Sexual and Reproductive
Health. 49-1 (1): 17-27.
Murtagh, Chloe; Wells, Elisa; Raymond, Elizabeth G.; Coeytaux, Francine; and Winikoff,
Beverly. (2018). "Exploring the feasibility of obtaining mifepristone and misoprostol
from the internet". Contraception. 97 (4): 287-291.
Mylonaki, I., Allémann, E., Saucy, F., Haefliger, J.-A., Delie, F., and Jordan, O., (2017).
Perivascular medical devices and drug delivery systems: Making the right choices.
Biomaterials, 128: 56-68